In Vivo's Deals Of The Month, February 2018

In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)

IV_DOTM_1200

Gilead Sciences Inc. will pay up to $3.16 billion for exclusive rights to gene editing pioneer Sangamo Therapeutics Inc.'s zinc finger nuclease technology to help its Kite Pharma Inc. subsidiary create better T cell therapies for cancer. In seeking a partner, Gilead eschewed newer gene editing plays, describing Sangamo's ZFN technology as "the optimal gene editing platform." The partners have identified some initial oncology targets for specific therapeutic programs and will also attempt to develop CAR-T therapies for solid tumors. [See Deal]

mRNA drug developer Moderna Therapeutics LLC added $500 million to its already-full coffers in early February. New investors Abu...

More from Deal-Making

More from In Vivo